All In Biotech

Drug Trial Radar · NCT02291289

A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)

A Multi-Centre Randomised Clinical Trial of Biomarker-Driven Maintenance Treatment for First-Line Metastatic Colorectal Cancer (MODUL)

Last checked: Nov 19, 2026Latest source record: May 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,044 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,044

Actual

Start

Apr 17, 2015

Primary completion

May 31, 2019

Study completion Mar 24, 2021

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Nov 14, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, multi-center, active-controlled, open-label, parallel-group study will investigate the efficacy and safety of biomarker-driven maintenance treatment for first-line mCRC. Participants with mCRC are eligible for entry and cannot have received any prior chemotherapy in the metastatic setting. The entire study duration is anticipated to be approximately 7.5 years.

Conditions

  • Colorectal Cancer

Interventions

  • CetuximabDrug

    500 mg/m\^2 via IV infusion on Day 1 of every 2-week cycle

  • FOLFOX induction regimenDrug

    Administered per the Investigator's discretion in accordance with locally approved prescribing information.

  • Fluoropyrimidine (5-FU/LV or capecitabine)Drug

    Per Investigator's discretion: 5-FU 1600-2400 mg/m\^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m\^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.

  • AtezolizumabDrug

    800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle, or a fixed dose of 840 mg

  • VemurafenibDrug

    960 mg vermurafenib BID by mouth

  • BevacizumabDrug

    5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information

  • TrastuzumabDrug

    Initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses by IV infusion on Day 1 of every 3-week treatment cycle

  • PertuzumabDrug

    Initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses by IV infusion on Day 1 of each 3-week treatment cycle

  • CobimetinibDrug

    60 mg orally once daily for 3 weeks followed by a 1-week treatment break

  • 5-FU/LVDrug

    1600-2400 mg/m\^2 5-FU via 46-hour IV infusion in combination with 400 mg/m\^2 LV via 2-hour infusion on Day 1 of every 2-week cycle until disease progression per the Investigator's assessment using modified Response Evaluation Criteria in Solid Tumors or death from any cause, whichever occurs first. The fluoropyrimidine should be administered in accordance with local prescribing information.

  • CapecitabineDrug

    1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The fluoropyrimidine should be administered in accordance with local prescribing information.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: From randomization until disease progression or death from any cause, up to 5 years

Locations

154 sites in 23 countries. Site status is shown where the registry gives one.

  • Hospital de Gastroenterologia Dr. Bonorino Udaondo ; Servicio de Oncología

    Buenos Aires, Argentina

  • Centro Oncologico Riojano Integral (CORI)

    La Rioja, Argentina

  • Clínica Viedma

    Viedma Rio Negro, Argentina

  • Institut Jules Bordet X

    Brussels, Belgium

  • Hospital Erasme

    Brussels, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • CHC MontLégia

    Liège, Belgium

  • AZ Delta (Campus Rumbeke)

    Roeselare, Belgium

  • University Clinical Center of the Republic of Srpska

    Banja Luka, Bosnia and Herzegovina

  • Hospital da Cidade de Passo Fundo; Centro de Pesquisa em Oncologia

    Passo Fundo, Rio Grande do Sul, Brazil

  • Hospital das Clinicas - UFRGS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Nossa Senhora da Conceicao

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Cancer de Barretos

    Barretos, São Paulo, Brazil

  • Hospital Amaral Carvalho

    Jaú, São Paulo, Brazil

  • Faculdade de Medicina de Sao Jose do Rio Preto - FAMERP*X*

    São José do Rio Preto, São Paulo, Brazil

  • Instituto de Ensino e Pesquisa Sao Lucas - IEP

    São Paulo, São Paulo, Brazil

  • Herlev Hospital; Afdeling for Kræftbehandling

    Herlev, Denmark

  • Regionshospitalet Gødstrup; Kræftafdelingen

    Herning, Denmark

  • Rigshospitalet; Onkologisk Klinik

    København Ø, Denmark

  • Odense Universitetshospital, Onkologisk Afdeling R

    Odense C, Denmark

  • Sygehus Syd Roskilde; Onkologisk/haematologisk ambulatorium

    Roskilde, Denmark

  • National Cancer Institute

    Cairo, Egypt

  • Ain Shams University Hospital; Oncology

    Cairo, Egypt

  • Clinique Sainte Catherine

    Avignon, France

  • HOPITAL JEAN MINJOZ; Oncologie

    Besançon, France

  • Hopital Augustin Morvan; Federation De Cancerologie

    Brest, France

  • Chu Estaing; Chir Generale Digestive A Et B

    Clermont-Ferrand, France

  • Hôpital Franco-Britannique- Fondation Cognacq-Jay; Cancerologie

    Levallois-Perret, France

  • Hopital Claude Huriez; Medecine Interne Oncologie

    Lille, France

  • Ch De Montbeliard;Chir Generale Digestive

    Montbéliard, France

  • Hopital Caremeau; Gastro Enterologie

    Nîmes, France

  • Hopital Saint Antoine; Oncologie Medicale

    Paris, France

  • Hopital Haut Leveque

    Pessac, France

  • Chu La Miletrie; Gastro Enterologie Endoscopies

    Poitiers, France

  • ICANS

    Strasbourg, France

  • Hopital Rangueil; Gastro Enterologie Et Nutrition

    Toulouse, France

  • Institut Gustave Roussy; Departement Oncologie Medicale

    Villejuif, France

  • Hämatologie Onkologie im Zentrum MVZ GmbH

    Augsburg, Germany

  • Onkologische Schwerpunktpraxis Kurfürstendamm

    Berlin, Germany

  • DRK Kliniken Berlin Köpenick Darmzentrum

    Berlin, Germany

Showing 40 of 154 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.